Dear Friend,
This week, news media have been reporting early results from the PASADENA study, a Phase II clinical trial of a potential new Parkinson’s treatment called prasinezumab, which targets the protein alpha-synuclein. The study, sponsored by the pharmaceutical company Roche and the biotechnology company Prothena, is testing this therapy as a strategy to clear alpha-synuclein clumps believed to give rise to Parkinson’s.
While the trial did not meet its primary endpoint, it did show early signals of success on several secondary measures. We talked to two of the scientists who led the study to bring you in-depth analysis of what they found and plans for next steps. Read the interview on our website.
Sincerely,
The Michael J. Fox Foundation |
|
|
No hay comentarios:
Publicar un comentario